Comparative Pharmacology
Head-to-head clinical analysis: AZASITE versus ETHRIL 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZASITE versus ETHRIL 250.
AZASITE vs ETHRIL 250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
ETHRIL 250 (valproate semisodium) increases GABA levels in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, enhancing neuronal inhibition.
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
250 mg orally every 8 hours, or 500 mg intravenously every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
Terminal elimination half-life of 6-8 hours in adults; prolonged to 12-15 hours in renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
Primarily renal elimination (70-80% unchanged), with 10-15% biliary/fecal elimination as metabolites; total clearance approximates 150 mL/min.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic